SOMATOSTATIN RECEPTORS SCINTIGRAPHY PRIORITIZATION CRITERIA BASED ON NET PATIENT EPIDEMIOLOGICAL PROFILE: A BI-CENTRIC STUDY

  • Cati Raluca STOLNICEANU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Cipriana STEFANESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • T.M. IONESCU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Irena GRIEROSU “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • W. JALLOUL “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Roxana IACOB “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Ana-Maria STATESCU “Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania
  • V. GHIZDOVAT “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • C. VOLOVAT “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Doina AZOICAI “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • Simona VOLOVAT “Grigore T. Popa” University of Medicine and Pharmacy Iasi
  • M. MATOVIC University Clinical Center of Kragujevac, Serbia

Abstract

This study aimed to create a generic profile of patients with NETs and to establish the prioritization criteria for somatostatin receptors scintigraphy (SRS), within the NETs diagnostic algorithm, being the first study of this kind conducted in Romania. Material and methods: A bi-centric, retro-prospective study comprising 103 patients with NETs, evaluated through 99mTc-TOC SRS, in two nuclear medicine departments from “Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania and Center of Nuclear Medicine, University Clinical Center of Kragujevac, Serbia. We analyzed the clinical-paraclinical features of included patients, as a starting point for streamlining the selection of patients for SRS. Results and discussion: The total group of patients included 47.57 % men and 52.43 % women, the age varying between 21-83 years. The most frequent primary NETs were represented by pNETs, and GI-NETs and the symptoms were nonspecific for majority of analyzed patients. Both prospective and retrospective analysis showed that SRS was followed by positive results. For prospectively analyzed patients, due to the used customized sheets, it was extremely easy to identify four SRS prioritization criteria. Conclusions: This study could outline the profile of patients with NETs, as the starting point for streamlining patient selection for SRS. The four prioritization criteria proposed by us could guide the diagnostic algorithm.

Author Biographies

Cipriana STEFANESCU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania

Irena GRIEROSU, “Grigore T. Popa” University of Medicine and Pharmacy Iasi

“Sf. Spiridon” County Clinical Emergency Hospital Iasi, Romania

M. MATOVIC, University Clinical Center of Kragujevac, Serbia

Center of Nuclear Medicine

References

1. Półtorak-Szymczak G, Budlewski T, Furmanek MI, et al. Radiological Imaging of Gastro-Entero-Pancreatic Neuroendocrine Tumors. The Review of Current Literature Emphasizing the Diagnostic Value of Chosen Imaging Methods. Front Oncol 2021; 11: 670233 / doi.org/10.3389/ fonc.2021. 670233.
2. Stolniceanu CR, Nistor I, Bilha SC, et al. Nephrotoxicity/renal failure after therapy with 90Ytrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. Nucl Med Commun 2020; 41(7): 601-617 / doi: 10.1097/MNM.0000000000001198.
3. Balon HR, Brown TL, Goldsmith SJ, et al. Society of Nuclear Medicine. The SNM practice guideline for somatostatin receptor scintigraphy 2.0. J Nucl Med Technol 2011; 39: 317-324.
4. Darbà J, Marsà A. Exploring the current status of neuroendocrine tumours: a population-based analysis of epidemiology, management and use of resources. BMC Cancer 2019; 19(1): 1226 / doi: 10.1186/s12885-019-6412-8.
5. Kilickap S, Hayran KM. Epidemiology of Neuroendocrine Tumors. In: Yalcin S, Öberg K, editors. Neuroendocrine Tumours. Berlin, Heidelberg: Springer-Verlag, 2015.
6. Das S, Dasari A. Epidemiology, Incidence, and Prevalence of Neuroendocrine Neoplasms: Are There Global Differences? Curr Oncol Rep 2021; 23(4): 43 / doi: 10.1007/s11912-021-01029-7.
7. van der Zwan JM, Trama A, Otter R, et al. Rare neuroendocrine tumors: Results of the surveillance of rare cancers in Europe project. European Journal of Cancer 2013; 49(11): 2565-2578.
8. Santos A, Santos A, Castro C, et al. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers 2018; 10(9): 293 / doi: 10.3390/cancers10090293.
Published
2021-09-30
Section
PREVENTIVE MEDICINE - LABORATORY